I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 9 studies | 30% ± 9% | |
| endothelial cell | 7 studies | 18% ± 2% | |
| hepatocyte | 5 studies | 44% ± 20% | |
| epithelial cell | 4 studies | 29% ± 14% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 9 studies | 30% ± 9% | |
| endothelial cell | 7 studies | 18% ± 2% | |
| hepatocyte | 5 studies | 44% ± 20% | |
| epithelial cell | 4 studies | 29% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 6486.08 | 226 / 226 | 100% | 66.86 | 406 / 406 |
| ovary | 100% | 1404.94 | 180 / 180 | 100% | 19.79 | 430 / 430 |
| prostate | 100% | 1967.34 | 245 / 245 | 100% | 39.96 | 502 / 502 |
| lung | 100% | 1621.52 | 578 / 578 | 100% | 26.14 | 1153 / 1155 |
| esophagus | 100% | 970.37 | 1444 / 1445 | 99% | 15.46 | 182 / 183 |
| stomach | 100% | 1093.51 | 358 / 359 | 100% | 20.68 | 285 / 286 |
| breast | 100% | 1582.47 | 458 / 459 | 100% | 33.99 | 1113 / 1118 |
| uterus | 100% | 874.42 | 170 / 170 | 99% | 24.27 | 453 / 459 |
| thymus | 100% | 971.77 | 653 / 653 | 98% | 17.42 | 595 / 605 |
| pancreas | 100% | 1840.09 | 328 / 328 | 98% | 19.82 | 174 / 178 |
| skin | 100% | 1252.48 | 1809 / 1809 | 97% | 17.92 | 457 / 472 |
| brain | 99% | 1464.30 | 2625 / 2642 | 97% | 16.92 | 687 / 705 |
| intestine | 97% | 789.09 | 937 / 966 | 99% | 23.31 | 523 / 527 |
| bladder | 95% | 730.86 | 20 / 21 | 100% | 24.21 | 502 / 504 |
| kidney | 100% | 4347.11 | 89 / 89 | 92% | 27.26 | 832 / 901 |
| adrenal gland | 95% | 473.99 | 245 / 258 | 50% | 5.17 | 114 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 35.35 | 29 / 29 |
| spleen | 100% | 965.60 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 21.93 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 15.79 | 1 / 1 |
| adipose | 100% | 833.00 | 1202 / 1204 | 0% | 0 | 0 / 0 |
| heart | 99% | 824.44 | 852 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 98% | 650.53 | 1305 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 16.96 | 77 / 80 |
| muscle | 84% | 384.56 | 671 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 46% | 420.45 | 425 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0019441 | Biological process | tryptophan catabolic process to kynurenine |
| GO_0034354 | Biological process | 'de novo' NAD biosynthetic process from tryptophan |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0004061 | Molecular function | arylformamidase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | AFMID |
| Protein name | AFMID protein Arylformamidase Kynurenine formamidase (KFA) (KFase) (EC 3.5.1.9) (Arylformamidase) (N-formylkynurenine formamidase) (FKF) |
| Synonyms | hCG_29397 |
| Description | FUNCTION: Catalyzes the hydrolysis of N-formyl-L-kynurenine to L-kynurenine, the second step in the kynurenine pathway of tryptophan degradation. Kynurenine may be further oxidized to nicotinic acid, NAD(H) and NADP(H). Required for elimination of toxic metabolites. . |
| Accessions | Q63HM1 W4VSQ7 A5PLM3 ENST00000327898.9 [Q63HM1-2] K7EIX3 ENST00000589256.5 K7ELV9 K7EK09 ENST00000591952.5 ENST00000588800.5 K7EQK5 ENST00000586542.5 ENST00000586731.1 K7EPF8 K7EMI4 ENST00000589107.5 ENST00000409257.10 [Q63HM1-1] K7EMM5 ENST00000588199.5 ENST00000591256.5 |
